the jackson clinical knowledgebase (jax-ckbtm) (Jackson Laboratory)
90
Structured Review
Jackson Laboratory
the jackson clinical knowledgebase (jax-ckbtm)
The Jackson Clinical Knowledgebase (Jax Ckbtm), supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/the+jackson+clinical+knowledgebase+(jax-ckbtm)/jackson+clinical+knowledgebase/10__1200_slash_jco__2024__42__16_suppl__e13508-5-32-36
Average 90 stars, based on 1 article reviews
The Jackson Clinical Knowledgebase (Jax Ckbtm), supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/the+jackson+clinical+knowledgebase+(jax-ckbtm)/jackson+clinical+knowledgebase/10__1200_slash_jco__2024__42__16_suppl__e13508-5-32-36
Average 90 stars, based on 1 article reviews
the jackson clinical knowledgebase (jax-ckbtm) - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Variant Assay:Article Title: NGS panels' capture of biomarkers associated with targeted therapies in clinical trials. Article Snippet: Background: ASCO and NCCN guidelines strongly encourage participation in clinical trials though participation rates remain low.. Although up to 60% of trials require biomarker information as a prerequisite to participation, guidelines are silent on biomarker testing to assess eligibility.. To help inform policy development, we analyzed commercially available NGS panels to assess the capture rate of the specific gene variants required for targeted therapies in clinical trials. Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Clinical Proteomics:Article Title: NGS panels' capture of biomarkers associated with targeted therapies in clinical trials. Article Snippet: Background: ASCO and NCCN guidelines strongly encourage participation in clinical trials though participation rates remain low.. Although up to 60% of trials require biomarker information as a prerequisite to participation, guidelines are silent on biomarker testing to assess eligibility.. To help inform policy development, we analyzed commercially available NGS panels to assess the capture rate of the specific gene variants required for targeted therapies in clinical trials. Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. |